LUX-Lung: Determining the best EGFR inhibitor in NSCLC?

The Lancet Oncology

Volumn 16, Issue 2, 2015, Pages 118-119

  Rossi, Antonio ^a   Di Maio, Massimo ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

CANCER SURVIVAL; DRUG CHOICE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EGFR GENE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GENE MUTATION; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG ADENOCARCINOMA; NON SMALL CELL LUNG CANCER; NOTE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR GENE; ADENOCARCINOMA; FEMALE; GENETICS; LUNG NEOPLASMS; MALE; MUTATION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84921864537     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71196-9     Document Type: Note

References (9)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
2. Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015, published online Jan 12. http://dx.doi.org/10.1016/S1470-2045(14)71173-8.
3. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013, 105:595-605.
4. Lagakos SW The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006, 354:1667-1669.
5. Hotta K, Suzuki E, Di Maio M, et al. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer 2013, 79:20-26.
6. Spicer JF, Rudman SM EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol 2010, 5:245-255.
7. Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease. A retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 2012, 7:1722-1727.
8. Riely GJ, Pao W, Pham DK, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:839-844.
9. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914.